Welcome to another edition of Endpoints Weekly — and happy spring! The weather may not feel very spring-like here in NYC (outside that false start

The FDA is seeking feedback ahead of a public meeting this summer to evaluate the progress of a voucher pilot that has so far accelerated

The lead drug pricing negotiator at the White House said the overarching goal of TrumpRx is to improve price transparency, not to be a large

Plus, news about Gilead, Assembly Biosciences and Pfizer: 📁 Sarepta says FDA open to a filing for full approval of two Duchenne drugs: After a

The UK’s drug watchdog is reconsidering two Alzheimer’s disease medicines after rejecting them for being too expensive. The National Institute for Health and Care Excellence